Mydecine Innovations Group Appoints Josephine Wu to Board of Directors
February 03, 2021 07:30 ET
|
Mydecine Innovations Group Inc.
DENVER, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to...
Mydecine Innovations Group Receives Conditional Approval to List on NEO Exchange
February 01, 2021 07:30 ET
|
Mydecine Innovations Group Inc.
DENVER, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), an emerging biopharma and life sciences company committed to...
Mydecine Innovations Group Sponsors Study on Neuron Level Response to Psilocybin at University of Maryland
January 28, 2021 07:30 ET
|
Mydecine Innovations Group Inc.
DENVER, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to...
Mydecine Innovations Group Files Application to list to the NASDAQ
January 27, 2021 07:30 ET
|
Mydecine Innovations Group Inc.
DENVER, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to...
Mydecine Innovations Group Included in First-Ever Psychedelics ETF
January 22, 2021 07:30 ET
|
Mydecine Innovations Group Inc.
DENVER, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to...
Mydecine Innovations Group Appoints Gordon Neal to Board of Directors and Dean Ditto as Chief Financial Officer
January 11, 2021 07:30 ET
|
Mydecine Innovations Group Inc.
DENVER, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to...
Mydecine Innovations Group Shares Intellectual Property Update
January 07, 2021 07:30 ET
|
Mydecine Innovations Group Inc.
Company files seven provisional patent applications with United States Patent and Trademark Office DENVER, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF)...
Mydecine Innovations Group Sponsors First Lab-Based Study of Established Microdosers at Macquarie University in Australia
January 05, 2021 07:30 ET
|
Mydecine Innovations Group Inc.
DENVER, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to...
Mydecine Innovations Group Engages ethica CRO as Contract Research Organization Partner for Phase 2A PTSD Clinical Trials
December 21, 2020 07:30 ET
|
Mydecine Innovations Group Inc.
DENVER, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the...
Mydecine Innovations Group Engages the ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials
December 15, 2020 07:30 ET
|
Mydecine Innovations Group Inc.
DENVER, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the...